Fig. 2

Heatmaps with unsupervised hierarchical clustering based on the tissue miRNA levels: (a) 386 unique miRNAs with padj < 0.05 derived from the likelihood ratio test; (b) top 20 most significant miRNAs across all tumor origins (padj < 0.05); (c) 99 deregulated miRNAs distinguishing colorectal carcinoma brain metastases (BMC) from breast carcinoma brain metastases (BMB); (d) 178 deregulated miRNAs differentiating non-small cell lung carcinoma brain metastases (BML) from BMB; (e) 161 deregulated miRNAs distinguishing BMB from melanoma brain metastases (BMM); (f) 85 deregulated miRNAs differentiating renal cell carcinoma brain metastases (BMR) from BMB; (g) 223 deregulated miRNAs distinguishing BMC from BML; (h) 224 deregulated miRNAs differentiating BMM from BMC; (i) 181 deregulated miRNAs distinguishing BMC from BMR; (j) 116 deregulated miRNAs differentiating BMM from BMR; (k) 89 deregulated miRNAs distinguishing BMR from BML; (l) 70 deregulated miRNAs differentiating BMM from BML, (padj < 0.05, |log₂FC|≥ 0.585 for all comparisons in panels (b–l).